Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NEOBIL: Neoadjuvant Bintrafusp alfa in resectable biliary tract cancer
2020-002605-25Phase 2Completed
- Sponsor
- AIO-Studien
- Start
- Nov 2020
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of bintrafusp alfa in biliary cancer and cholangiocarcinoma (CCA), sponsored by AIO-Studien. Primary endpoint: Major pathological response. Started Nov 2020; status: completed.
02
Drugs
bintrafusp alfa
03
Conditions
biliary cancercholangiocarcinoma (CCA)
Beyond the preview
Go deeper on 2020-002605-25.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-002605-25.